Possible mechanisms for the skeletal effects of antipsychotics in children and adolescents

Therapeutic Advances in Psychopharmacology

Volumn 3, Issue 5, 2013, Pages 278-293

  Calarge, Chadi A ^a   Ivins, Stephanie D ^a   Motyl, Katherine J ^b   Shibli Rahhal, Amal A ^c   Bliziotes, Michael M ^c   Schlechte, Janet A ^a  

^a UNIVERSITY OF IOWA   (United States)

^b Maine Medical Center Research Institute   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

antipsychotics; bone metabolism; hyperprolactinemia; osteoporosis; psychopathology; skeletal development

Indexed keywords

EID: 84997907195     PISSN: 20451253     EISSN: 20451261     Source Type: Journal    
DOI: 10.1177/2045125313487548     Document Type: Article

References (121)

1. Abraham G. Paing W. Kaminski J. Joseph A. Kohegyi E. Josiassen R. (2003) Effects of elevated serum prolactin on bone mineral density and bone metabolism in female patients with schizophrenia: a prospective study. Am J Psychiatry 160: 1618–1620.
2. Anderson G. Scahill L. McCracken J. McDougle C. Aman M. Tierney E. et al. (2007) Effects of short- and long-term risperidone treatment on prolactin levels in children with autism. Biol Psychiatry 61: 545–550.
3. Bachrach L. Sills I. (2011) Clinical report-bone densitometry in children and adolescents. Pediatrics 127: 189–194.
4. Baim S. Leonard M. Bianchi M. Hans D. Kalkwarf H. Langman C. et al. (2008) Official positions of the International Society for Clinical Densitometry and executive summary of the 2007 ISCD Pediatric Position Development Conference. J Clin Densitom 11: 6–21.
5. Barkey R. Ben-Shachar D. Amit T. Youdim M. (1985) Increased hepatic and reduced prostatic prolactin (PRL) binding in iron deficiency and during neuroleptic treatment: correlation with changes in serum PRL and testosterone. Eur J Pharmacol 109: 193–200.
6. Baudry A. Bitard J. Mouillet-Richard S. Locker M. Poliard A. Launay J. et al. (2010) Serotonergic 5-HT(2b) receptor controls tissue-nonspecific alkaline phosphatase activity in osteoblasts via eicosanoids and phosphatidylinositol-specific phospholipase C. J Biol Chem 285: 26066–26073.
7. Becker D. Liver O. Mester R. Rapoport M. Weizman A. Weiss M. (2003) Risperidone, but not olanzapine, decreases bone mineral density in female premenopausal schizophrenia patients. J Clin Psychiatry 64: 761–766.
8. Bilici M. Cakirbay H. Guler M. Tosun M. Ulgen M. Tan U. (2002) Classical and atypical neuroleptics, and bone mineral density, in patients with schizophrenia. Int J Neurosci 112: 817–828.
9. Biller B. Baum H. Rosenthal D. Saxe V. Charpie P. Klibanski A. (1992) Progressive trabecular osteopenia in women with hyperprolactinemic amenorrhea. J Clin Endocrinol Metab 75: 692–697.
10. Bliziotes M. Eshleman A. Zhang X. Wiren K. (2001) Neurotransmitter action in osteoblasts: expression of a functional system for serotonin receptor activation and reuptake. Bone 29: 477–486.
11. Bymaster F. Nelson D. DeLapp N. Falcone J. Eckols K. Truex L. et al. (1999) Antagonism by olanzapine of dopamine D1, serotonin2, muscarinic, histamine H1 and alpha 1-adrenergic receptors in vitro. Schizophrenia research 37: 107–122.
12. Calarge C. Acion L. Kuperman S. Tansey M. Schlechte J. (2009a) Weight gain and metabolic abnormalities during extended risperidone treatment in children and adolescents. J Child Adolesc Psychopharmacol 19: 101–109.
13. Calarge C. Ellingrod V. Acion L. Miller D. Moline J. Tansey M. et al. (2009b) Variants of the dopamine D2 receptor gene and risperidone-induced hyperprolactinemia in children and adolescents. Pharmacogenet Genomics 19: 373–382.
14. Calarge C. Ellingrod V. Zimmerman B. Bliziotes M. Schlechte J. (2011) Variants of the serotonin transporter gene, selective serotonin reuptake inhibitors, and bone mineral density in risperidone-treated boys: a reanalysis of data from a cross-sectional study with emphasis on pharmacogenetics. J Clin Psychiatry 72: 1685–1690.
15. Calarge C. Ziegler E. (2013) Iron deficiency in pediatric patients in long-term risperidone treatment. J Child Adolesc Psychopharmacol 23: 101–109.
16. Calarge C. Zimmerman B. Xie D. Kuperman S. Schlechte J. (2010) A cross-sectional evaluation of the effect of risperidone and selective serotonin reuptake inhibitors on bone mineral density in boys. J Clin Psychiatry 71: 338–347.
17. Carrie Fassler A. Bonjour J. (1995) Osteoporosis as a pediatric problem. Pediatr Clin N Am 42: 811–824.
18. Charoenphandhu N. Limlomwongse L. Krishnamra N. (2001) Prolactin directly stimulates transcellular active calcium transport in the duodenum of female rats. Can J Physiol Pharmacol 79: 430–438.
19. Charoenphandhu N. Teerapornpuntakit J. Methawasin M. Wongdee K. Thongchote K. Krishnamra N. (2008) Prolactin decreases expression of Runx2, osteoprotegerin, and RANKL in primary osteoblasts derived from tibiae of adult female rats. Can J Physiol Pharmacol 86: 240–248.
20. Clement-Lacroix P. Ormandy C. Lepescheux L. Ammann P. Damotte D. Goffin V. et al. (1999) Osteoblasts are a new target for prolactin: analysis of bone formation in prolactin receptor knockout mice. Endocrinology 140: 96–105.
21. Colao A. Di Somma C. Loche S. Di Sarno A. Klain M. Pivonello R. et al. (2000) Prolactinomas in adolescents: persistent bone loss after 2 years of prolactin normalization. Clin Endocrinol (Oxf) 52: 319–327.
22. Colao A. Loche S. Cappa M. Di Sarno A. Landi M. Sarnacchiaro F. et al. (1998) Prolactinomas in children and adolescents. clinical presentation and long-term follow-up. J Clin Endocrinol Metab 83: 2777–2780.
23. Collet C. Schiltz C. Geoffroy V. Maroteaux L. Launay J. de Vernejoul M. (2008) The serotonin 5-HT2b receptor controls bone mass via osteoblast recruitment and proliferation. FASEB J 22: 418–427.
24. Comer J. Olfson M. Mojtabai R. (2010) National trends in child and adolescent psychotropic polypharmacy in office-based practice, 1996–2007. J Am Acad Child Adolesc Psychiatry 49: 1001–1010.
25. Cooper W. Arbogast P. Ding H. Hickson G. Fuchs D. Ray W. (2006) Trends in prescribing of antipsychotic medications for US children. Ambulatory Pediatr 6: 79–83.
26. Correll C. Carlson H. (2006) Endocrine and metabolic adverse effects of psychotropic medications in children and adolescents. J Am Acad Child Adolesc Psychiatry 45: 771–791.
27. Correll C. Manu P. Olshanskiy V. Napolitano B. Kane J. Malhotra A. (2009) Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. JAMA 302: 1765–1773.
28. Coss D. Yang L. Kuo C. Xu X. Luben R. Walker A. (2000) Effects of prolactin on osteoblast alkaline phosphatase and bone formation in the developing rat. Am J Physiol Endocrinol Metab 279: E1216–E1225.
29. Costa J. Smith G. Watson M. Lin J. Callon K. Gamble G. et al. (2011) The atypical anti-psychotic clozapine decreases bone mass in rats in vivo. Schizophr Res 126: 291–297.
30. Crystal S. Olfson M. Huang C. Pincus H. Gerhard T. (2009) Broadened use of atypical antipsychotics: safety, effectiveness, and policy challenges. Health Aff (Millwood) 28: w770–w781.
31. dosReis S. Zito J. Safer D. Gardner J. Puccia K. Owens P. (2005) Multiple psychotropic medication use for youths: a two-state comparison. J Child Adolesc Psychopharmacol 15: 68–77.
32. Ducy P. (2011) 5-HT and bone biology. Curr Opin Pharmacol 11: 34–38.
33. Duffy F. Narrow W. Rae D. West J. Zarin D. Rubio-Stipec M. et al. (2005) Concomitant pharmacotherapy among youths treated in routine psychiatric practice. J Child Adolesc Psychopharmacol 15: 12–25.
34. Dunbar F. Kusumakar V. Daneman D. Schulz M. (2004) Growth and sexual maturation during long-term treatment with risperidone. Am J Psychiatry 161: 918–920.
35. Duntas L. (2001) Prolactinomas in children and adolescents – consequences in adult life. J Pediatr Endocrinol Metab 14(Suppl 5): 1227–1232; discussion 1261–1222.
36. Erdogan A. Atasoy N. Akkurt H. Ozturk D. Karaahmet E. Yalug I. et al. (2008) Risperidone and liver function tests in children and adolescents: a short-term prospective study. Prog Neuropsychopharmacol Biol Psychiatry 32: 849–857.
37. Erdogan A. Karaman M. Ozdemir E. Yurteri N. Tufan A. Kurcer M. (2010) Six months of treatment with risperidone may be associated with nonsignificant abnormalities of liver function tests in children and adolescents: a longitudinal, observational study from Turkey. J Child Adolesc Psychopharmacol 20: 407–413.
38. FDA (2006) FDA approves the first drug to treat irritability associated with autism, risperdal. Available at: http://www.fda.gov/bbs/topics/NEWS/2006/NEW01485.html
39. FDA (2007) Recommendation of approvable action for risperidone (Risperdal®) for the treatment of schizophrenia and bipolar I disorder in pediatric patients (response to PWR). Available at: http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/DevelopmentResources/UCM163241.pdf
40. FDA (2009) Seroquel® (quetiapine fumarate) tablets for the treatment of pediatric patients with schizophrenia (13-17 years old) or bipolar mania (10–17 years old). Briefing document for Psychopharmacologic Drugs Advisory Committee Meeting, 9–10 June 2009. Available at: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/PsychopharmacologicDrugsAdvisoryCommittee/UCM164280.pdf
41. Findling R. Johnson J. McClellan J. Frazier J. Vitiello B. Hamer R. et al. (2010) Double-blind maintenance safety and effectiveness findings from the Treatment of Early-Onset Schizophrenia Spectrum (TEOSS) study. J Am Acad Child Adolesc Psychiatry 49: 583–594; quiz 632.
42. Findling R. Kusumakar V. Daneman D. Moshang T. De Smedt G. Binder C. (2003) Prolactin levels during long-term risperidone treatment in children and adolescents. J Clin Psychiatry 64: 1362–1369.
43. Findling R. Robb A. Nyilas M. Forbes R. Jin N. Ivanova S. et al. (2008) A multiple-center, randomized, double-blind, placebo-controlled study of oral aripiprazole for treatment of adolescents with schizophrenia. Am J Psychiatry 165: 1432–1441.
44. Fricke O. Schoenau E. (2007) The ‘functional muscle-bone unit’: probing the relevance of mechanical signals for bone development in children and adolescents. Growth Horm IGF Res 17: 1–9.
45. Frost H. (1987) Bone ‘mass’ and the ‘mechanostat’: a proposal. Anat Rec 219: 1–9.
46. Fuh G. Colosi P. Wood W.I. Wells J.A. (1993) Mechanism-Based Design of Prolactin Receptor Antagonists. J Biol Chem 268: 5376–5381.
47. Geller B. Luby J. Joshi P. Wagner K. Emslie G. Walkup J. et al. (2012) A randomized controlled trial of risperidone, lithium, or divalproex sodium for initial treatment of bipolar I disorder, manic or mixed phase, in children and adolescents. Arch Gen Psychiatry 69: 515–528.
48. Greenspan S. Oppenheim D. Klibanski A. (1989) Importance of gonadal steroids to bone mass in men with hyperprolactinemic hypogonadism. Ann Intern Med 110: 526–531.
49. Halbreich U. Kinon B. Gilmore J. Kahn L. (2003) Elevated prolactin levels in patients with schizophrenia: mechanisms and related adverse effects. Psychoneuroendocrinology 28(Suppl. 1): 53–67.
50. Howes O. Wheeler M. Meaney A. O’Keane V. Fogelman I. Blake G. et al. (2005) Bone mineral density and its relationship to prolactin levels in patients taking antipsychotic treatment. J Clin Psychopharmacol 25: 259–261.
51. Huang H. Brennan T. Muir M. Mason R. (2009) Functional alpha1- and beta2-adrenergic receptors in human osteoblasts. J Cell Physiol 220: 267–275.
52. Ilondo M. Damholt A. Cunningham B. Wells J. De Meyts P. Shymko R. (1994) Receptor dimerization determines the effects of growth hormone in primary rat adipocytes and cultured human IM-9 lymphocytes. Endocrinology 134: 2397–2403.
53. Jung D. Conley R. Kelly D. Kim D. Yoon S. Jang J. et al. (2006) Prevalence of bone mineral density loss in Korean patients with schizophrenia: a cross-sectional study. J Clin Psychiatry 67: 1391–1396.
54. Karsenty G. Ducy P. (2006) The hypothalamic control of bone mass, implication for the treatment of osteoporosis. Ann Endocrinol (Paris) 67: 123.
55. Kelly T. Specker B. Binkley T. Zemel B. Leonard M. Kalkward H. et al. (2005) Pediatric BMD reference database for U.S. white children. Bone 36(Suppl. 1): S30.
56. Kishimoto T. Watanabe K. Shimada N. Makita K. Yagi G. Kashima H. (2008) Antipsychotic-induced hyperprolactinemia inhibits the hypothalamo-pituitary-gonadal axis and reduces bone mineral density in male patients with schizophrenia. J Clin Psychiatry 69: 385–391.
57. Klibanski A. Neer R. Beitins I. Ridgway E. Zervas N. McArthur J. (1980) Decreased bone density in hyperprolactinemic women. N Engl J Med 303: 1511–1514.
58. Kovacs C. Chik C. (1995) Hyperprolactinemia caused by lactation and pituitary adenomas is associated with altered serum calcium, phosphate, parathyroid hormone (PTH), and PTH-related peptide levels. J Clin Endocrinol Metab 80: 3036–3042.
59. Kryzhanovskaya L. Schulz S. McDougle C. Frazier J. Dittmann R. Robertson-Plouch C. et al. (2009) Olanzapine versus placebo in adolescents with schizophrenia: a 6-week, randomized, double-blind, placebo-controlled trial. J Am Acad Child Adolesc Psychiatry 48: 60–70.
60. Kumra S. Frazier J. Jacobsen L. McKenna K. Gordon C. Lenane M. et al. (1996) Childhood-onset schizophrenia. a double-blind clozapine-haloperidol comparison. Arch Gen Psychiatry 53: 1090–1097.
61. Kumra S. Herion D. Jacobsen L. Briguglia C. Grothe D. (1997) Case study: risperidone-induced hepatotoxicity in pediatric patients. J Am Acad Child Adolesc Psychiat 36: 701–705.
62. Kunimatsu T. Kimura J. Funabashi H. Inoue T. Seki T. (2010) The antipsychotics haloperidol and chlorpromazine increase bone metabolism and induce osteopenia in female rats. Regul Toxicol Pharmacol 58: 360–368.
63. Langer G. Sachar E. Halpern F. Gruen P. Solomon M. (1977) The prolactin response to neuroleptic drugs. a test of dopaminergic blockade: neuroendocrine studies in normal men. J Clin Endocrinol Metab 45: 996–1002.
64. Lewiecki E. Baim S. Langman C. Bilezikian J. (2009) Official positions of the International Society for Clinical Densitometry: perceptions and commentary. J Clin Densitom 12: 267–271.
65. Leysen J. Janssen P. Gommeren W. Wynants J. Pauwels P. Janssen P. (1992) In vitro and in vivo receptor binding and effects on monoamine turnover in rat brain regions of the novel antipsychotics risperidone and ocaperidone. Mol Pharmacol 41: 494–508.
66. Locker M. Bitard J. Collet C. Poliard A. Mutel V. Launay J. et al. (2006) Stepwise control of osteogenic differentiation by 5-HT(2B) receptor signaling: nitric oxide production and phospholipase A2 activation. Cell Signal 18: 628–639.
67. Lotinun S. Limlomwongse L. Krishnamra N. (1998) The study of a physiological significance of prolactin in the regulation of calcium metabolism during pregnancy and lactation in rats. Can J Physiol Pharmacol 76: 218–228.
68. Lotinun S. Limlomwongse L. Sirikulchayanonta V. Krishnamra N. (2003) Bone calcium turnover, formation, and resorption in bromocriptine- and prolactin-treated lactating rats. Endocrine 20: 163–170.
69. Mainoya J. (1975) Further studies on the action of prolactin on fluid and ion absorption by the rat jejunum. Endocrinology 96: 1158–1164.
70. Manna P. El-Hefnawy T. Kero J. Huhtaniemi I. (2001) Biphasic action of prolactin in the regulation of murine Leydig tumor cell functions. Endocrinology 142: 308–318.
71. Marder S. Essock S. Miller A. Buchanan R. Casey D. Davis J. et al. (2004) Physical health monitoring of patients with schizophrenia. Am J Psychiatry 161: 1334–1349.
72. Matkovic V. (1996) Skeletal development and bone turnover revisited. J Clin Endocrinol Metab 81: 2013–2016.
73. Matkovic V. Ilich J. Skugor M. Saracoglu M. (1995) Primary prevention of osteoporosis. Phys Med Rehab Clin North Am 6: 595–627.
74. Meaney A. O’Keane V. (2007) Bone mineral density changes over a year in young females with schizophrenia: relationship to medication and endocrine variables. Schizophr Res 93: 136–143.
75. Meaney A. Smith S. Howes O. O’Brien M. Murray R. O’Keane V. (2004) Effects of long-term prolactin-raising antipsychotic medication on bone mineral density in patients with schizophrenia. Br J Psychiatry 184: 503–508.
76. Modder U. Achenbach S. Amin S. Riggs B. Melton L. 3rd Khosla S. (2010) Relation of serum serotonin levels to bone density and structural parameters in women. J Bone Miner Res 25: 415–422.
77. Motyl K. Dick-de-Paula I. Maloney A. Lotinun S. Bornstein S. de Paula F. et al. (2012) Trabecular bone loss after administration of the second-generation antipsychotic risperidone is independent of weight gain. Bone 50: 490–498.
78. NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy (2001) Osteoporosis prevention, diagnosis, and therapy. JAMA 285: 785–795.
79. Oh-ie K. Miyazaki T. Koyama I. Hokari S. Komoda T. (2002) Altered bone turnover in chlorpromazine-challenged rats and its effect on 1alpha-hydroxyvitamin D3 administration in vivo. J Bone Miner Metab 20: 21–27.
80. Olfson M. Blanco C. Liu S. Wang S. Correll C. (2012) National trends in the office-based treatment of children, adolescents, and adults with antipsychotics. Arch Gen Psychiatry 69: 1247-1256.
81. Olfson M. Crystal S. Huang C. Gerhard T. (2010) Trends in antipsychotic drug use by very young, privately insured children. J Am Acad Child Adolesc Psychiatry 49: 13–23.
82. Pavuluri M. Henry D. Findling R. Parnes S. Carbray J. Mohammed T. et al. (2010) Double-blind randomized trial of risperidone versus divalproex in pediatric bipolar disorder. Bipolar Dis 12: 593–605.
83. Phillip M. Lazar L. (2003) The regulatory effect of hormones and growth factors on the pubertal growth spurt. Endocrinologist 13: 465–469.
84. Pitukcheewanont P. Chen P. (2005) Bone density measurements in children and adolescents. quantitative computed tomography versus dual-energy x-ray absorptiometry. Endocrinologist 15: 232–239.
85. Pringsheim T. Lam D. Ching H. Patten S. (2011) Metabolic and neurological complications of second-generation antipsychotic use in children: a systematic review and meta-analysis of randomized controlled trials. Drug Safety 34: 651–668.
86. Rauch F. Schoenau E. (2001) Changes in bone density during childhood and adolescence: an approach based on bone's biological organization. J Bone Miner Res 16: 597–604.
87. Research Units on Pediatric Psychopharmacology Autism Network (2005) Risperidone treatment of autistic disorder: longer-term benefits and blinded discontinuation after 6 months. Am J Psychiatry 162: 1361–1369.
88. Reyes M. Buitelaar J. Toren P. Augustyns I. Eerdekens M. (2006a) A randomized, double-blind, placebo-controlled study of risperidone maintenance treatment in children and adolescents with disruptive behavior disorders. Am J Psychiatry 163: 402–410.
89. Reyes M. Croonenberghs J. Augustyns I. Eerdekens M. (2006b) Long-term use of risperidone in children with disruptive behavior disorders and subaverage intelligence: efficacy, safety, and tolerability. J Child Adolesc Psychopharmacol 16: 260–272.
90. Reyes M. Olah R. Csaba K. Augustyns I. Eerdekens M. (2006c) Long-term safety and efficacy of risperidone in children with disruptive behaviour disorders. results of a 2-year extension study. Eur Child Adolesc Psychiatry 15: 97–104.
91. Richelson E. Souder T. (2000) Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci 68: 29–39.
92. Roke Y. van Harten P. Boot A. Buitelaar J. (2009) Antipsychotic medication in children and adolescents: a descriptive review of the effects on prolactin level and associated side effects. J Child Adolesc Psychopharmacol 19: 403–414.
93. Roth B. Sheffler D. Kroeze W. (2004) Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia. Nat Rev Drug Discov 3: 353–359.
94. Sackett G. Unis A. Crouthamel B. (2010) Some effects of risperidone and quetiapine on growth parameters and hormone levels in young pigtail macaques. J Child Adolesc Psychopharmacol 20: 489–493.
95. Safer D. (2011) Age-grouped differences in adverse drug events from psychotropic medication. J Child Adolesc Psychopharmacol 21: 299–309.
96. Safer D. Calarge C. Safer A. (2013) Prolactin serum concentrations during aripiprazole treatment in youth. J Child Adolesc Psychopharmacol, in press.
97. Schlechte J. Sherman B. Martin R. (1983) Bone density in amenorrheic women with and without hyperprolactinemia. J Clin Endocrinol Metab 56: 1120–1123.
98. Schlechte J. Walkner L. Kathol M. (1992) A longitudinal analysis of premenopausal bone loss in healthy women and women with hyperprolactinemia. J Clin Endocrinol Metab 75: 698–703.
99. Schoenau E. (2005) From mechanostat theory to development of the ‘functional muscle-bone-unit’. J Musculoskelet Neuronal Interact 5: 232–238.
100. Seriwatanachai D. Charoenphandhu N. Suthiphongchai T. Krishnamra N. (2008a) Prolactin decreases the expression ratio of receptor activator of nuclear factor kappaB ligand/osteoprotegerin in human fetal osteoblast cells. Cell Biol Int 32: 1126-1135.
101. Seriwatanachai D. Krishnamra N. van Leeuwen J. (2009) Evidence for direct effects of prolactin on human osteoblasts: inhibition of cell growth and mineralization. J Cell Biochem 107: 677–685.
102. Seriwatanachai D. Thongchote K. Charoenphandhu N. Pandaranandaka J. Tudpor K. Teerapornpuntakit J. et al. (2008b) Prolactin directly enhances bone turnover by raising osteoblast-expressed receptor activator of nuclear factor kappaB ligand/osteoprotegerin ratio. Bone 42: 535–546.
103. Shibli-Rahhal A. Schlechte J. (2009) The effects of hyperprolactinemia on bone and fat. Pituitary 12: 96–104.
104. Sikich L. Frazier J. McClellan J. Findling R. Vitiello B. Ritz L. et al. (2008) Double-blind comparison of first- and second-generation antipsychotics in early-onset schizophrenia and schizo-affective disorder: findings from the Treatment of Early-Onset Schizophrenia Spectrum Disorders (TEOSS) study. Am J Psychiatry 165: 1420–1431.
105. Specker B. Schoenau E. (2005) Quantitative bone analysis in children: current methods and recommendations. J Pediatr 146: 726–731.
106. Stiegler C. Leb G. Kleinert R. Warnkross H. Ramschak-Schwarzer S. Lipp R. et al. (1995) Plasma levels of parathyroid hormone-related peptide are elevated in hyperprolactinemia and correlated to bone density status. J Bone Miner Res 10: 751–759.
107. Styne D. (2002) The testes, disorders of sexual differentiation and puberty in the male. In: Sperling M. (ed.), Pediatric endocrinology, 2nd ed. Philadelphia, PA: Sauders.
108. Tanrattana C. Charoenphandhu N. Limlomwongse L. Krishnamra N. (2004) Prolactin directly stimulated the solvent drag-induced calcium transport in the duodenum of female rats. Biochim Biophys Act 1665: 81–91.
109. Theintz G. Buchs B. Rizzoli R. Slosman D. Clavien H. Sizonenko P. et al. (1992) Longitudinal monitoring of bone mass accumulation in healthy adolescents: evidence for a marked reduction after 16 years of age at the levels of lumbar spine and femoral neck in female subjects. J Clin Endocrinol Metab 75: 1060–1065.
110. Togari A. (2002) Adrenergic regulation of bone metabolism: possible involvement of sympathetic innervation of osteoblastic and osteoclastic cells. Microscopy Res Technique 58: 77–84.
111. Tohen M. Kryzhanovskaya L. Carlson G. Delbello M. Wozniak J. Kowatch R. et al. (2007) Olanzapine versus placebo in the treatment of adolescents with bipolar mania. Am J Psychiatry 164: 1547–1556.
112. Tudpor K. Charoenphandhu N. Saengamnart W. Krishnamra N. (2005) Long-term prolactin exposure differentially stimulated the transcellular and solvent drag-induced calcium transport in the duodenum of ovariectomized rats. Exp Biol Med 230: 836–844.
113. Vitiello B. Correll C. van Zwieten-Boot B. Zuddas A. Parellada M. Arango C. (2009) Antipsychotics in children and adolescents: increasing use, evidence for efficacy and safety concerns. Eur Neuropsychopharmacol 19: 629–635.
114. Warden S. Hassett S. Bond J. Rydberg J. Grogg J. Hilles E. et al. (2010) Psychotropic drugs have contrasting skeletal effects that are independent of their effects on physical activity levels. Bone 46: 985–992.
115. Warden S. Robling A. Haney E. Turner C. Bliziotes M. (2010) The emerging role of serotonin (5-hydroxytryptamine) in the skeleton and its mediation of the skeletal effects of low-density lipoprotein receptor-related protein 5 (LRP5). Bone 46: 4–12.
116. Westbroek I. van der Plas A. de Rooij K. Klein-Nulend J. Nijweide P. (2001) Expression of serotonin receptors in bone. J Biol Chem 276: 28961–28968.
117. Yadav V. Ryu J. Suda N. Tanaka K. Gingrich J. Schutz G. et al. (2008) LRP5 controls bone formation by inhibiting serotonin synthesis in the duodenum. Cell 135: 825–837.
118. Yang L. Grey V. (2006) Pediatric reference intervals for bone markers. Clin Biochem 39: 561–568.
119. Zamani A. Omrani G. Nasab M. (2009) Lithium's effect on bone mineral density. Bone 44: 331–334.
120. Zemel B. Leonard M. Kalkward H. Specker B. Moyer-Mileur L. Shepherd J. et al. (2004) Reference data for the whole body, lumbar spine, and proximal femur for American children relative to age, gender, and body size. J Bone Miner Res 19: S231.
121. Zuddas A. Zanni R. Usala T. (2011) Second generation antipsychotics (SGAs) for non-psychotic disorders in children and adolescents: a review of the randomized controlled studies. Eur Neuropsychopharmacol 21: 600–620.